MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage

MIRA reports significant weight and fat reduction with oral SKNY-1 in obese mice, with favorable lea

Key Findings From the SKNY-1 Pilot StudyStatistically Significant Weight and Fat ReductionOral SKNY-

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage

MIAMI, Oct. 22, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "C

Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 11.8% to $0.44 during Monday's

Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 12.9% to $4.24 during Friday's after-mark

Maxim Group analyst Jason McCarthy initiates coverage on Mira Pharmaceuticals (NASDAQ:MIRA) with

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage

MIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - Miravalles Gold Corp. (CSE: MIRA

MIRA Pharmaceuticals (NASDAQ: MIRA) stock jumps as MIRA-55 meets key preclinical study milestones fo

Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regu

MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "

Obesity Treatment Candidate Designed to Preserve Lean Body Mass Toxicokinetic Findings De-Risk Dose

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-mark

MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "C

Optimized Oral Formulation Demonstrates Favorable Oral Bioavailability Together with Robust Brain an

Optimized Oral Formulation Demonstrates Favorable Oral Bioavailability Together with Robust Brain an

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage

New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver

Study Overview and Key FindingsResearchers tested THC and Mira-55, along with rimonabant's abili

Data show Mira-55 does not produce the central nervous system effects associated with THC and acts t

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage

Randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and dose-respon

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Agreement Establishes Global Exclusivity Across MIRA's Core Therapeutic Pipeline and Enhances St

Agreement Establishes Global Exclusivity Across MIRA's Core Therapeutic Pipeline and Enhances Strate

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage

Expanded Global Intellectual Property Portfolio Enhances Strategic Flexibility and Long-Term Value P

Selective oral NMDA receptor modulator demonstrated favorable safety, tolerability, and pharmacokine

Selective oral NMDA receptor modulator demonstrated favorable safety, tolerability, and pharmacokine

The publication, titled "SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and At

Peer-reviewed publication highlights preclinical findings demonstrating weight loss, lipid normaliza

Edmonton, Alberta--(Newsfile Corp. - May 6, 2026) - Visionstate Corp. (TSXV: VIS) today reported its

MIRA Pharmaceuticals (NASDAQ: MIRA) eyes IND submission for Mira-55 after new 2026 data confirms no

Previously shown to deliver morphine-comparable pain relief without opioid-related risks in a valida

Previously shown to deliver morphine-comparable pain relief without opioid-related risks in a valida

Edmonton, Alberta--(Newsfile Corp. - March 18, 2026) - Visionstate Corp. (TSXV: VIS) today provided

Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced periphera

https://www.sec.gov/ix?doc=/Archives/edgar/data/1904286/000149315226008707/form8-k.htm

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA - Get Free Report) saw a large increase in short interest i

Phase 1 Progress and Phase 2a Development PlansThe ongoing randomized, double-blind, placebo-control

Mira Pharmaceuticals (NASDAQ:MIRA) reported quarterly losses of $(1.18) per share which missed the a

Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no appr

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company") announced that it